Breast Cancer | Specialty

HR+ mBC: Treatment After Progression on CDK4/6 Inhibition

November 30th 2018

HR+ mBC: Factors in Selecting CDK4/6 Inhibitions

November 30th 2018

Selecting Agents in CDK4/6 Inhibition for HR+ mBC

November 30th 2018

CDK4/6 Inhibition's Role in HR+ Metastatic Breast Cancer

November 30th 2018

Dr. Leon Ferre Discusses Ongoing Research in TNBC

November 30th 2018

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses ongoing research in triple-negative breast cancer (TNBC).

Some Women May Benefit From Mammography Screening Beginning at Age 30

November 29th 2018

Women between the ages of 30 and 39 who have at least 1 of 3 risk factors may benefit from starting their annual mammography screening at age 30.

O'Regan Highlights CDK4/6 Agents, Other Developments in ER+ Breast Cancer

November 27th 2018

Ruth O’Regan, MD, discusses the current landscape of hormone receptor–positive breast cancer and the unanswered questions that still need to be addressed.

Dr. Boughey on Surgical Management of Patients With Node-Positive Breast Cancer

November 27th 2018

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses the surgical management of patients with node-positive breast cancer.

Expert Reviews Data for Abemaciclib in Breast Cancer

November 27th 2018

The treatment options for women with hormone receptor (HR)–positive metastatic breast cancer have evolved rapidly in the past decade, with the introduction of the CDK4 and CDK6 inhibitors representing a major advance.

Lead Researcher Discusses Alpelisib in PIK3CA+ Breast Cancer

November 26th 2018

Fabrice Andre, MD, PhD, discusses the SOLAR-1 findings and their impact on the breast cancer landscape.

Brufsky Highlights Novel Approaches for TNBC

November 21st 2018

Adam M. Brufsky, MD, PhD, highlights novel treatment approaches being explored in the triple-negative breast cancer space.

Dr. Borgen on Precision Medicine in Breast Cancer

November 20th 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses the implementation of precision medicine in breast cancer.

Dr. Toomey Discusses Findings of TAILORx Trial

November 17th 2018

Kathleen Toomey, MD, who specializes in hematology and medical oncology and practices at the Steeplechase Cancer Center, discusses the results of the TAILORx trial, which reported that some patients with early-stage breast cancer can avoid chemotherapy.

Dr. Fitzgerald on Minimizing Use of Chemotherapy in Breast Cancer

November 17th 2018

Dennis Fitzgerald, MD, a specialist in breast cancer, lung cancer, non-Hodgkin lymphoma and hemochromatosis, Hackensack Meridian Health Riverview Medical Center, discusses the pivotal TAILORx trial.

EU Panel Backs Expanding Ribociclib Approval in HR+/HER2- Breast Cancer

November 17th 2018

The European Medicine’s Agency Committee for Medicinal Products for Human Use has recommended expanding the approval of ribociclib (Kisqali) in women with HR+/HER2-negative breast cancer to include use in combination with fulvestrant (Faslodex).

Dr. Rugo on Resistance to CDK4/6 Inhibitors in HR+ Breast Cancer

November 14th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses resistance to CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

FDA Grants Atezolizumab Combo Priority Review for Frontline TNBC

November 13th 2018

The FDA has granted a priority review designation to a supplemental biologics license application for the frontline combination of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

Dr. Evans on the Tolerability of CDK4/6 Inhibitors in HR+ Breast Cancer

November 9th 2018

Terry L. Evans, MD, clinical assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the tolerability of CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

Low NR2F1 Expression May Predict Risk of Metastatic Breast Cancer

November 7th 2018

Low NR2F1 expression in disseminated tumor cells (DTCs) that is found in bone marrow may be indicative of developing metastatic breast cancer, according to results of a study published in Breast Cancer Research.

Dr. Andre on Rationale for SOLAR-1 Trial in Breast Cancer

November 3rd 2018

Fabrice Andre, MD, PhD, professor of medical oncology, Institut Gustave Roussy, Villejuif, France, discusses the rationale for the SOLAR-1 trial in breast cancer.